Pfizer wins approval for pneumonia vaccine
Washington, February 24, 2010
US health officials have approved Pfizer's new version of a blockbuster vaccine that fights pneumonia, meningitis and other diseases caused by pneumococcus bacteria, a company spokeswoman said.
Prevnar 13 was the most important experimental product the company acquired in last year's purchase of Wyeth. The vaccine fights 13 strains of streptococcus pneumoniae bacteria.
The original Prevnar, which targeted seven strains, was introduced in 2000 and has annual sales around $3 billion.
BMO Capital Markets analyst Robert Hazlett has estimated sales for the Prevnar franchise will hit $3.7 billion in 2012. - Reuters
More Health & Environment Stories
- NCDs ‘to cost GCC $36bn in 2013’
- Arabtec inks $1.2bn UAE hospital contract
- Infectious disease control ‘urgent need for GCC’
- New HIV cases fall as Bahrain's efforts pay off
- Conference to discuss emergency medicine
- UAE reports 3 more MERS cases
- Bahrain 'free of Mers coronavirus'
- 500,000 suffer from spinal cord injuries
- 3BL to assess Majaal corporate sustainability
- Diabetes experts to meet in Abu Dhabi